ClinicalTrials.gg
CompletedNCT02980731VENICE IIUpdated Feb 22, 2023Results posted

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

A Phase 3 interventional study of Venetoclax in Chronic Lymphocytic Leukemia (CLL), sponsored by AbbVie. Completed at 33 sites in 10 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
14th of 69
210 · median 72
Started
2016
with 5 others
Phase 3
15 of 69
3 open now
Registered
19th of 69
by date
Lead sponsor
11 of 69
AbbVie

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 6 that started in 2016, is one of 15 in phase 3, and was the 19th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of cancer affecting the blood and the bone marrow) with or without the 17p deletion or TP53 mutation, including participants with an unknown status, as well as R/R CLL participants who had been previously treated with B-cell receptor inhibitor (BCRi) therapy. The starting dose of venetoclax was 20 mg once daily. The dose must have been gradually increased over a period of 5 weeks up to the daily dose of 400 mg. Participants may have continued receiving venetoclax for up to 2 years. After the treatment period, participants may have continued on into a 2-year follow-up period.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)

Keywords

  • Relapsed CLL
  • Refractory CLL
  • 17p deletion
  • TP53 gene
  • B-Cell receptor inhibitor (BCRi)
  • European Organization of Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
  • Overall response rate (ORR)
  • Duration of overall response (DOR)
  • Complete remission rate (CR + CRi)
  • Progression-free survival (PFS)
  • Overall survival (OS)
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance score of ≤ 2
  • Participant has disease (received at least one prior therapy)
  • Diagnosis of CLL that meets published 2008 Modified International Workshop on CLL National Cancer Institute - Working Group (IWCLL NCI-WG) Guidelines and:

    • has an indication for treatment according to the 2008 Modified IWCLL NCI-WG Guidelines
    • has clinically (lymphocytosis > 5 × 10\^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)
    • with or without 17p deletion or TP53 mutation
    • may have been previously treated with a prior B-cell receptor inhibitor therapy
  • Adequate bone marrow function

Exclusion criteria

Exclusion Criteria:

  • Participant has developed Richter's transformation or Prolymphocytic leukemia (PLL)
  • Participant has previously received venetoclax
  • History of active other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:

    • adequately treated in situ carcinoma of the cervix uteri
    • adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
    • previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
  • Active and uncontrolled cytopenias (within 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP), despite low dose
  • Prior stem cell transplant
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Venetoclax

    Venetoclax was administered orally once daily (QD) for a planned duration of up to 2 years or until disease progression; median time on treatment was 127 weeks. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.

    Drug: Venetoclax

Interventions

  • Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.

    Also known as: ABT-199, VENCLEXTA, VENCLYXTO

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Mean Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  2. Mean Change From Baseline in Physical Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a physical functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the physical functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  3. Mean Change From Baseline in Role Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a role functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the role functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  4. Mean Change From Baseline in Emotional Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an emotional functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the emotional functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  5. Mean Change From Baseline in Cognitive Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a cognitive functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the cognitive functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  6. Mean Change From Baseline in Social Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a social functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  7. Mean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a fatigue scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  8. Mean Change From Baseline in Nausea and Vomiting Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a nausea and vomiting scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the nausea and vomiting scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  9. Mean Change From Baseline in Pain Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a pain scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the pain scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  10. Mean Change From Baseline in Dyspnea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a dyspnea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the dyspnea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  11. Mean Change From Baseline in Insomnia Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an insomnia scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the insomnia scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  12. Mean Change From Baseline in Appetite Loss Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an appetite loss scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the appetite loss scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  13. Mean Change From Baseline in Constipation Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a constipation scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the constipation scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  14. Mean Change From Baseline in Diarrhea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a diarrhea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the diarrhea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  15. Mean Change From Baseline in Financial Difficulties Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a financial difficulties scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the financial difficulties scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  16. Mean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

    EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  17. Mean Change From Baseline in Treatment Side Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

    EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the treatment side effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  18. Mean Change From Baseline in Disease Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

    EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the disease effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  19. Mean Change From Baseline in Infection Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

    EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the infection scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  20. Mean Change From Baseline in Social Problems Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

    EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social problems scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  21. Mean Change From Baseline in Future Health Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

    EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the future health scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  22. Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale Score

    The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). Participants rated their health on a vertical visual analogue scale, where the endpoints were labelled 100, "The best health you can imagine" and 0, "The worst health you can imagine". Positive values indicate improvement from baseline.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  23. Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Health Index Score

    The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). The scores for the 5 dimensions are used to compute a single utility index score ranging from zero (0.0) to 1 (1.0) representing the general health status of the individual, with '0' defined as a health state equivalent to being dead and '1' is full health. The higher the score the better the health status. Positive values indicate improvement from baseline.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)

  24. Complete Remission Rate (Complete Remission [CR] + Complete Remission With Incomplete Marrow Recovery [CRi])

    Complete remission rate (CR + CRi) is defined as the percentage of participants achieving a CR or CRi as their best response (per the investigator assessment) based on 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria.

    Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks

  25. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria as assessed by investigator using the best response at any time during the study.

    Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks

  26. Duration of Overall Response (DOR)

    DoR is defined as the number of days from the date of first response (complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria to the earliest date of progressive disease (PD) or death. DOR was analyzed by Kaplan-Meier (K-M) methodology.

    Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks

  27. Time to Progression (TTP)

    TTP is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.

    Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks

  28. Progression-Free Survival (PFS)

    PFS is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.

    Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks

  29. Overall Survival (OS)

    OS is defined as the number of days from the date of first dose of venetoclax to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.

    Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks

07

Results

Posted Feb 22, 2023

Participant flow

Participant flow — Overall Study
MilestoneVenetoclax
Started210
Completed0
Not completed210
Withdrew: Death63
Withdrew: Withdrawal by subject6
Withdrew: Lost to follow-up5
Withdrew: Study terminated by sponsor4
Withdrew: Completed survival follow-up period65
Withdrew: Covid-19 infection1
Withdrew: Other, not specified66

Outcome measures

PrimaryMean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Mean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Mean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)9.3 ± 20.11
Statistical analysis
  • Venetoclax · t-test, 2 sided · p = =0.004 (P-value is derived from a paired t-test of H0: mean difference (Week 48 - baseline) ≤ 5 versus H1: mean difference (Week 48 - baseline) \> 5)
SecondaryMean Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 43.9 ± 17.65
Week 86.0 ± 20.67
Week 127.6 ± 20.13
Week 249.2 ± 20.29
Week 369.4 ± 19.45
Week 489.3 ± 20.11
Week 6010.3 ± 21.83
Week 7210.2 ± 23.87
Week 8411.2 ± 20.96
Week 968.9 ± 20.92
Week 1089.2 ± 19.97
Final visit4.8 ± 23.58
SecondaryMean Change From Baseline in Physical Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a physical functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the physical functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Physical Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 41.2 ± 12.86
Week 83.0 ± 16.16
Week 124.6 ± 15.89
Week 245.2 ± 16.90
Week 365.6 ± 15.59
Week 486.1 ± 16.30
Week 606.0 ± 17.73
Week 725.7 ± 18.47
Week 844.8 ± 15.04
Week 964.0 ± 17.18
Week 1085.7 ± 16.43
Final visit1.8 ± 20.52
SecondaryMean Change From Baseline in Role Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a role functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the role functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Role Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 42.6 ± 22.75
Week 84.0 ± 28.31
Week 127.1 ± 28.60
Week 249.2 ± 26.85
Week 369.8 ± 26.70
Week 4810.4 ± 26.10
Week 608.4 ± 27.63
Week 7211.6 ± 31.01
Week 849.9 ± 27.38
Week 968.3 ± 31.23
Week 10811.5 ± 28.03
Final visit3.3 ± 33.29
SecondaryMean Change From Baseline in Emotional Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an emotional functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the emotional functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Emotional Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 44.9 ± 16.30
Week 84.7 ± 16.96
Week 125.7 ± 17.11
Week 243.6 ± 17.62
Week 364.3 ± 17.08
Week 485.7 ± 17.64
Week 605.2 ± 18.79
Week 725.1 ± 18.54
Week 844.0 ± 17.95
Week 964.2 ± 19.95
Week 1086.1 ± 20.18
Final visit1.4 ± 21.78
SecondaryMean Change From Baseline in Cognitive Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a cognitive functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the cognitive functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Cognitive Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 42.3 ± 15.61
Week 84.2 ± 18.93
Week 124.3 ± 18.29
Week 243.4 ± 18.42
Week 363.8 ± 18.54
Week 483.7 ± 17.15
Week 604.1 ± 20.01
Week 724.7 ± 17.65
Week 843.5 ± 17.91
Week 961.1 ± 19.58
Week 1085.6 ± 18.75
Final visit2.3 ± 20.79
SecondaryMean Change From Baseline in Social Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a social functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Social Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 42.2 ± 19.14
Week 85.5 ± 22.13
Week 126.6 ± 22.26
Week 247.2 ± 24.79
Week 368.6 ± 21.63
Week 489.9 ± 22.80
Week 609.2 ± 25.78
Week 729.7 ± 27.41
Week 848.7 ± 23.95
Week 968.2 ± 26.14
Week 10811.7 ± 24.21
Final visit3.4 ± 29.70
SecondaryMean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a fatigue scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-4.6 ± 18.63
Week 8-7.7 ± 22.70
Week 12-11.2 ± 24.66
Week 24-10.9 ± 20.70
Week 36-12.5 ± 23.21
Week 48-12.9 ± 21.40
Week 60-13.0 ± 22.79
Week 72-13.8 ± 25.90
Week 84-12.9 ± 23.49
Week 96-10.7 ± 24.13
Week 108-13.8 ± 22.69
Final visit-7.5 ± 26.16
SecondaryMean Change From Baseline in Nausea and Vomiting Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a nausea and vomiting scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the nausea and vomiting scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Nausea and Vomiting Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-0.2 ± 18.02
Week 80.4 ± 17.19
Week 12-0.3 ± 18.50
Week 24-1.5 ± 17.24
Week 36-2.0 ± 16.19
Week 48-0.6 ± 19.45
Week 60-0.3 ± 15.42
Week 720.3 ± 17.40
Week 840.4 ± 18.00
Week 960.1 ± 17.15
Week 108-1.1 ± 16.28
Final visit-0.8 ± 17.58
SecondaryMean Change From Baseline in Pain Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a pain scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the pain scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Pain Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-4.6 ± 21.05
Week 8-2.9 ± 21.31
Week 12-3.6 ± 22.56
Week 24-4.1 ± 22.08
Week 36-4.0 ± 22.43
Week 48-4.6 ± 20.29
Week 60-5.2 ± 23.46
Week 72-4.7 ± 23.30
Week 84-4.6 ± 22.10
Week 961.1 ± 25.35
Week 108-3.4 ± 24.33
Final visit-0.1 ± 26.50
SecondaryMean Change From Baseline in Dyspnea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a dyspnea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the dyspnea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Dyspnea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-3.7 ± 23.33
Week 8-5.5 ± 26.62
Week 12-7.7 ± 29.08
Week 24-8.5 ± 26.56
Week 36-8.3 ± 28.43
Week 48-8.5 ± 27.19
Week 60-8.5 ± 26.08
Week 72-9.2 ± 31.30
Week 84-9.3 ± 26.84
Week 96-6.4 ± 28.55
Week 108-10.9 ± 27.92
Final visit-5.3 ± 29.60
SecondaryMean Change From Baseline in Insomnia Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an insomnia scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the insomnia scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Insomnia Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-6.5 ± 25.78
Week 8-7.9 ± 30.39
Week 12-9.1 ± 29.27
Week 24-9.0 ± 27.19
Week 36-8.3 ± 30.68
Week 48-11.6 ± 25.77
Week 60-10.2 ± 28.94
Week 72-7.8 ± 29.40
Week 84-9.5 ± 28.35
Week 96-6.6 ± 29.76
Week 108-10.7 ± 26.16
Final visit-5.3 ± 30.52
SecondaryMean Change From Baseline in Appetite Loss Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an appetite loss scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the appetite loss scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Appetite Loss Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-3.4 ± 23.63
Week 8-6.2 ± 24.85
Week 12-6.0 ± 29.56
Week 24-8.8 ± 27.36
Week 36-8.1 ± 24.06
Week 48-7.8 ± 24.14
Week 60-5.6 ± 27.16
Week 72-5.1 ± 27.59
Week 84-6.9 ± 24.16
Week 96-6.4 ± 27.07
Week 108-9.3 ± 25.81
Final visit-4.0 ± 30.36
SecondaryMean Change From Baseline in Constipation Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a constipation scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the constipation scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Constipation Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 41.7 ± 17.87
Week 82.5 ± 21.38
Week 121.4 ± 20.58
Week 241.1 ± 18.61
Week 36-0.8 ± 20.36
Week 48-0.2 ± 18.35
Week 601.7 ± 20.52
Week 720.5 ± 18.97
Week 841.7 ± 19.45
Week 960.7 ± 20.55
Week 108-0.8 ± 18.98
Final visit1.2 ± 19.64
SecondaryMean Change From Baseline in Diarrhea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a diarrhea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the diarrhea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Diarrhea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-0.7 ± 20.63
Week 81.8 ± 21.45
Week 122.3 ± 22.30
Week 244.7 ± 21.42
Week 364.6 ± 21.62
Week 484.0 ± 21.13
Week 607.4 ± 27.01
Week 723.0 ± 25.74
Week 844.3 ± 23.18
Week 963.7 ± 22.47
Week 1083.8 ± 21.51
Final visit4.9 ± 23.30
SecondaryMean Change From Baseline in Financial Difficulties Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a financial difficulties scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the financial difficulties scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Financial Difficulties Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
units on a scaleVenetoclax
Week 4-6.4 ± 20.07
Week 8-4.6 ± 21.91
Week 12-6.0 ± 24.54
Week 24-7.3 ± 25.05
Week 36-7.8 ± 23.70
Week 48-8.9 ± 26.52
Week 60-10.0 ± 25.96
Week 72-8.5 ± 27.99
Week 84-10.9 ± 23.06
Week 96-8.6 ± 25.34
Week 108-9.6 ± 24.04
Final visit-6.5 ± 25.88
SecondaryMean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
units on a scaleVenetoclax
Week 4-6.3 ± 32.20
Week 8-10.2 ± 38.11
Week 12-13.9 ± 38.59
Week 24-15.3 ± 37.96
Week 36-16.3 ± 34.41
Week 48-16.1 ± 35.41
Week 60-14.5 ± 36.59
Week 72-16.4 ± 36.85
Week 84-17.4 ± 34.90
Week 96-13.0 ± 35.18
Week 108-19.8 ± 35.17
Final visit-10.6 ± 41.71
SecondaryMean Change From Baseline in Treatment Side Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the treatment side effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Treatment Side Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
units on a scaleVenetoclax
Week 4-2.6 ± 17.70
Week 8-4.0 ± 17.84
Week 12-4.8 ± 17.96
Week 24-7.5 ± 18.46
Week 36-7.8 ± 18.03
Week 48-7.5 ± 19.19
Week 60-6.3 ± 19.41
Week 72-6.3 ± 18.73
Week 84-6.8 ± 16.43
Week 96-6.9 ± 18.48
Week 108-8.2 ± 19.33
Final visit-3.6 ± 22.54
SecondaryMean Change From Baseline in Disease Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the disease effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Disease Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
units on a scaleVenetoclax
Week 4-10.7 ± 19.58
Week 8-10.0 ± 21.80
Week 12-12.4 ± 23.48
Week 24-13.7 ± 23.63
Week 36-13.9 ± 23.34
Week 48-13.4 ± 23.68
Week 60-13.1 ± 23.18
Week 72-13.8 ± 23.22
Week 84-13.6 ± 22.69
Week 96-13.2 ± 22.59
Week 108-15.6 ± 24.93
Final visit-10.2 ± 25.97
SecondaryMean Change From Baseline in Infection Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the infection scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Infection Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
units on a scaleVenetoclax
Week 4-3.5 ± 21.66
Week 8-6.0 ± 29.00
Week 12-4.6 ± 28.67
Week 24-6.1 ± 26.50
Week 36-8.9 ± 26.04
Week 48-9.0 ± 25.54
Week 60-7.9 ± 25.13
Week 72-8.5 ± 28.97
Week 84-9.9 ± 24.18
Week 96-8.5 ± 25.34
Week 108-10.3 ± 25.41
Final visit-5.5 ± 29.97
SecondaryMean Change From Baseline in Social Problems Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social problems scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Social Problems Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
units on a scaleVenetoclax
Week 4-4.0 ± 37.50
Week 8-7.5 ± 39.15
Week 12-8.5 ± 41.06
Week 24-10.6 ± 41.72
Week 36-13.7 ± 38.15
Week 48-15.6 ± 40.85
Week 60-15.6 ± 37.18
Week 72-17.5 ± 42.76
Week 84-15.3 ± 42.14
Week 96-14.7 ± 41.79
Week 108-16.1 ± 43.85
Final visit-4.0 ± 48.50
SecondaryMean Change From Baseline in Future Health Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)

EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the future health scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Future Health Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
units on a scaleVenetoclax
Week 4-17.2 ± 37.82
Week 8-21.6 ± 42.94
Week 12-25.5 ± 41.77
Week 24-23.0 ± 38.96
Week 36-24.4 ± 43.97
Week 48-24.1 ± 41.75
Week 60-25.1 ± 46.09
Week 72-27.8 ± 40.59
Week 84-20.7 ± 39.68
Week 96-24.9 ± 44.18
Week 108-23.7 ± 46.63
Final visit-16.7 ± 49.90
SecondaryMean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale Score

The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). Participants rated their health on a vertical visual analogue scale, where the endpoints were labelled 100, "The best health you can imagine" and 0, "The worst health you can imagine". Positive values indicate improvement from baseline.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale Score
units on a scaleVenetoclax
Week 43.67 ± 12.683
Week 86.00 ± 15.982
Week 127.75 ± 14.498
Week 247.78 ± 16.158
Week 369.08 ± 16.342
Week 4810.34 ± 16.808
Week 6010.84 ± 17.180
Week 7211.19 ± 17.890
Week 8410.22 ± 15.431
Week 969.98 ± 16.310
Week 10810.77 ± 17.500
Final Visit6.22 ± 19.262
SecondaryMean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Health Index Score

The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). The scores for the 5 dimensions are used to compute a single utility index score ranging from zero (0.0) to 1 (1.0) representing the general health status of the individual, with '0' defined as a health state equivalent to being dead and '1' is full health. The higher the score the better the health status. Positive values indicate improvement from baseline.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Reported as:
Mean · units on a scale
Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Health Index Score
units on a scaleVenetoclax
Week 40.02 ± 0.135
Week 80.02 ± 0.130
Week 120.03 ± 0.122
Week 240.03 ± 0.112
Week 360.04 ± 0.121
Week 480.04 ± 0.124
Week 600.04 ± 0.129
Week 720.03 ± 0.132
Week 840.03 ± 0.111
Week 960.01 ± 0.134
Week 1080.02 ± 0.124
Final Visit-0.01 ± 0.172
SecondaryComplete Remission Rate (Complete Remission [CR] + Complete Remission With Incomplete Marrow Recovery [CRi])

Complete remission rate (CR + CRi) is defined as the percentage of participants achieving a CR or CRi as their best response (per the investigator assessment) based on 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria.

Time frame:
From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Reported as:
Number · percentage of participants
Complete Remission Rate (Complete Remission [CR] + Complete Remission With Incomplete Marrow Recovery [CRi])
percentage of participantsVenetoclax
Complete Remission Rate (Complete Remission [CR] + Complete Remission With Incomplete Marrow Recovery [CRi])18.6 (13.6 to 24.5)
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria as assessed by investigator using the best response at any time during the study.

Time frame:
From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsVenetoclax
Overall Response Rate (ORR)76.7 (70.4 to 82.2)
SecondaryDuration of Overall Response (DOR)

DoR is defined as the number of days from the date of first response (complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria to the earliest date of progressive disease (PD) or death. DOR was analyzed by Kaplan-Meier (K-M) methodology.

Time frame:
From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Reported as:
Median · months
Duration of Overall Response (DOR)
monthsVenetoclax
Duration of Overall Response (DOR)36.0 (30.0 to 38.9)
SecondaryTime to Progression (TTP)

TTP is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.

Time frame:
From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Reported as:
Median · months
Time to Progression (TTP)
monthsVenetoclax
Time to Progression (TTP)43.0 (33.4 to 47.2)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.

Time frame:
From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsVenetoclax
Progression-Free Survival (PFS)35.5 (32.9 to 42.9)
SecondaryOverall Survival (OS)

OS is defined as the number of days from the date of first dose of venetoclax to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.

Time frame:
From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Reported as:
Median · months
Overall Survival (OS)
monthsVenetoclax
Overall Survival (OS)NA (53.1 to NA)

Adverse events

Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was 184 weeks. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean duration on study drug was 123 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax65/210 (31%)106/210 (50.5%)179/210 (85.2%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventVenetoclax
PNEUMONIAInfections and infestations21/210
PYREXIAGeneral disorders10/210
FEBRILE NEUTROPENIABlood and lymphatic system disorders7/210
THROMBOCYTOPENIABlood and lymphatic system disorders6/210
ANAEMIABlood and lymphatic system disorders5/210
HYPERPHOSPHATAEMIAMetabolism and nutrition disorders5/210
AUTOIMMUNE HAEMOLYTIC ANAEMIABlood and lymphatic system disorders4/210
INFLUENZAInfections and infestations4/210
DIARRHOEAGastrointestinal disorders3/210
COVID-19 PNEUMONIAInfections and infestations3/210
Most frequent other events
Showing 10 of 25
Most frequent other events
EventVenetoclax
NEUTROPENIABlood and lymphatic system disorders90/210
DIARRHOEAGastrointestinal disorders66/210
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations58/210
THROMBOCYTOPENIABlood and lymphatic system disorders39/210
NAUSEAGastrointestinal disorders35/210
ANAEMIABlood and lymphatic system disorders26/210
ARTHRALGIAMusculoskeletal and connective tissue disorders21/210
COUGHRespiratory, thoracic and mediastinal disorders21/210
PYREXIAGeneral disorders19/210
HYPERTENSIONVascular disorders19/210

Baseline characteristics

All enrolled participants who received at least one dose of venetoclax

Age, Continuous
Age, Continuous(years)Venetoclax
Mean63.9 ± 10.37
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax
Female69
Male141
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Venetoclax
White182
Black or African American1
Asian18
American Indian or Alaska Native8
Native Hawaiian or other Pacific Islander1
Other0
08

Study locations

33 sites
  • Hospital Italiano La Plata /ID# 150812
    La Plata, Buenos Aires 1902, Argentina
  • Fundaleu /Id# 150811
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires 1114, Argentina
  • Cemic /Id# 150810
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires 1431, Argentina
  • Sanatorio Allende /ID# 150813
    Cordoba, 5000, Argentina
  • St George Hospital /ID# 154212
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital /ID# 154950
    Liverpool, New South Wales 2170, Australia
  • Gold coast University Hospital /ID# 150833
    SouthPort, Queensland 4215, Australia
  • Peter MacCallum Cancer Ctr /ID# 154948
    Melbourne, Victoria 3000, Australia
  • Perth Blood Institute Ltd /ID# 154949
    Nedlands, Western Australia 6009, Australia
  • UMHAT Alexandrovska EAD /ID# 162987
    Sofiya, Sofia 1431, Bulgaria
  • UMHAT Sveti Georgi /ID# 161594
    Plovdiv, 4002, Bulgaria
  • UMHAT Sveti Ivan Rilski /ID# 163280
    Sofia, 1431, Bulgaria
  • SHAT Hematologic Diseases /ID# 161592
    Sofia, 1756, Bulgaria
  • Prince of Wales Hospital /ID# 150837
    Hong Kong, 999077, Hong Kong
  • Queen Mary Hospital /ID# 150836
    Hong Kong, 999077, Hong Kong
  • Semmelweis Egyetem /ID# 150792
    Budapest, 1085, Hungary
  • Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 152842
    Budapest, 1097, Hungary
  • Centro de Investigacion Clínica Chapultepec SA de CV /ID# 163641
    Morelia, Michoacan 58260, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez /ID# 150821
    Monterrey, Nuevo Leon 64460, Mexico
  • Middlemore Clinical Trials /ID# 161526
    Papatoetoe, Auckland 2025, New Zealand
  • North Shore Hospital /ID# 157626
    Takapuna, Auckland 0622, New Zealand
  • Wellington Regional Hospital /ID# 157627
    Newtown, Wellington 6021, New Zealand
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopern /ID# 150880
    Lodz, Lodzkie 93-513, Poland
  • Instytut Hematologii i Transfuzjologii /ID# 150878
    Warszawa, Mazowieckie 02-776, Poland
  • Szpitale Pomorskie Sp. z o.o /ID# 164097
    Gdynia, Pomorskie 81-519, Poland
  • SP ZOZ Zespol Szpitali Miejskich w Chorzowie /ID# 150877
    Chorzow, Slaskie 41-500, Poland
  • Federal State Budgetary Scientific Institution N.N. Blokhin /ID# 166610
    Moscow, Moskva 115478, Russian Federation
  • Moscow State budget healthcare /ID# 154806
    Moscow, Moskva 125284, Russian Federation
  • Regional Oncological Dispensary /ID# 154202
    Penza, Penzenskaya Oblast 440071, Russian Federation
  • Federal State Budgetary Ins NRC for Hematology of MoH of Russian Federation /ID# 154213
    Moscow, 125167, Russian Federation
  • China Medical University Hospital /ID# 150839
    Taichung City, 40447, Taiwan
  • National Taiwan University Hospital /ID# 150838
    Taipei City, 100, Taiwan
  • Taipei Veterans General Hosp /ID# 153803
    Taipei City, 11217, Taiwan
09

References and documents

Publications

  • Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Sail KR, Pesko J, Pai M, Komlosi V, Anderson MA. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leuk Lymphoma. 2022 Feb;63(2):304-314. doi: 10.1080/10428194.2021.1986217. Epub 2021 Oct 11. PubMed 34632935 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Dec 2021, 60 months.

Results were first posted in Feb 2023, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 60 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2016
First posted
Dec 2, 2016
StartActual
Dec 13, 2016
Primary completionActual
Dec 29, 2021
CompletionActual
Dec 29, 2021
Results first posted
Feb 22, 2023
Last update
Feb 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02980731
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 2, 2016
Start date
Dec 13, 2016
Primary completion
Dec 29, 2021
Completion
Dec 29, 2021
Results posted
Feb 22, 2023
Last update
Feb 22, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion